Ocular Therapeutix Announces Proposed Public Offering of Common Stock

Ocular Therapeutix Announces Proposed

Public Offering of Common Stock

BEDFORD, Mass, December 14, 2020 - Ocular Therapeutix ,

Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies

for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of $75.0 million

of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase

up to an additional $11.25 million of its common stock. All of the shares in the offering are to be sold by the Company. The offering

is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Jefferies LLC and Piper Sandler & Co. are acting as joint

book-running managers for the offering.

The proposed offering is being made pursuant to a shelf registration

statement on Form S-3 which became automatically effective upon filing with the Securities and Exchange Commission (SEC). This

offering will be made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration

statement. Before investing in the offering, interested parties should read the prospectus supplement and the accompanying prospectus

for the offering and the other documents the Company has filed with the SEC, which are incorporated by reference in the prospectus

supplement and the accompanying prospectus for the offering and which provide more complete information about the Company and the

offering. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus for the offering will be available

on the website of the SEC at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating

to this offering may also be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department,

520 Madison Avenue, 2nd Floor, NY 10022, by telephone: (877) 821-7388, or by email: Prospectus_Department@Jefferies.com or Piper

Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924,

or by email: prospectus@psc.com.

This press release shall not constitute an offer to sell or

a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such

offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state

About Ocular Therapeutix, Inc.

Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative

therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.

Ocular Therapeutix's first commercial drug product, DEXTENZA , is FDA-approved for the treatment of ocular

inflammation and pain following ophthalmic surgery. Ocular Therapeutix is evaluating product candidates for the treatment of

other ocular conditions including various retinal diseases, glaucoma, dry eye disease, and allergic conjunctivitis.

Forward Looking Statements

Any statements in this press release about future expectations,

plans, and prospects for the Company, including the Company's expectations and plans regarding the proposed underwritten

public offering and the Company's anticipated use of proceeds of the offering, and other statements containing the words

"anticipate," "believe," "estimate," "expect," "intend", "goal,"

"may", "might," "plan," "predict," "project," "target,"

"potential," "will," "would," "could," "should," "continue,"

and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act

of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important

factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's clinical

development programs, future results, performance or achievements to differ significantly from those expressed or implied by the

forward-looking statements. Such risks and uncertainties include, among others, the severity and duration of the COVID-19 pandemic

including its effect on the Company's and relevant regulatory authorities' operations and the financial markets, the

final terms of the proposed underwritten offering, the satisfaction of customary closing conditions related to the proposed underwritten

public offering, the need for additional financing or other actions and other factors discussed in the "Risk Factors"

section contained in the preliminary prospectus supplement related to the proposed underwritten public offering and the Company's

quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included

in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent

events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking

statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law. These

forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the

date of this press release.

Chief Financial Officer

Westwicke, an ICR Company

Senior Vice President, Commercial